Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 19: Perindopril - Fibrinolyse Abb. 20: Perindopril - Antiatheriosklerotischer Effekt Abb. 21: Perindopril - Antiischämische Wirksamkeit Aktuelles Bild - Abb. 22: Perindopril - Verträglichkeit Abb. 23: Perindopril - Verträglichkeit Abb. 24: EUROPA-Studie - Studienziel Abb. 25: EUROPA-Studie - Endpunkte Zum letzten Bild
Abbildung 22: Perindopril - Verträglichkeit
First dose hypotension in heart failure patients with the initiation of an ACEI may be symptomatic or asymptomatic, which may lead to renal, cardiac, or cerebral hypoperfusion. In the double-blind, randomized, placebo-controlled, parallel-group prospective study of elderly patients with stable chronic heart failure, perindopril demonstrated an excellent hemodynamic tolerance minimizing the risk of hypotension. Perindopril 2 mg produces no more decrease in blood pressure then placebo. On the contrary, enalapril and captopril induce significant and long-lasting reduction in mean arterial pressure. Perindopril once daily provides an excellent hemodynamic profile even in fragile patients. So, for all these reasons perindopril was chosen to conduct EUROPA study. Mc Fadyen J, Lees K R, Reid J L. Br Heart J. 1991; 66: 206-11.
 
Perindopril - Verträglichkeit
Vorheriges Bild Nächstes Bild   


Abbildung 22: Perindopril - Verträglichkeit
First dose hypotension in heart failure patients with the initiation of an ACEI may be symptomatic or asymptomatic, which may lead to renal, cardiac, or cerebral hypoperfusion. In the double-blind, randomized, placebo-controlled, parallel-group prospective study of elderly patients with stable chronic heart failure, perindopril demonstrated an excellent hemodynamic tolerance minimizing the risk of hypotension. Perindopril 2 mg produces no more decrease in blood pressure then placebo. On the contrary, enalapril and captopril induce significant and long-lasting reduction in mean arterial pressure. Perindopril once daily provides an excellent hemodynamic profile even in fragile patients. So, for all these reasons perindopril was chosen to conduct EUROPA study. Mc Fadyen J, Lees K R, Reid J L. Br Heart J. 1991; 66: 206-11.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung